This anti-infective agent is primarily applied in contexts marked by active bacterial infections across several clinical domains. It is commonly used to help manage conditions such as bacterial skin infections (including impetigo and cellulitis) and eye infections (such as conjunctivitis).

---

Key Therapeutic Focus

The medication helps address symptom clusters that create noticeable physiological strain, commonly associated with conditions like impetigo, folliculitis, furuncles, and secondary infections complicating chronic skin issues like eczema. It is generally applied in scenarios where additional management of localized discomfort is required. The core benefit is providing support that helps ease the overall symptom burden.

Quick Fact: Relief for Inflammatory Skin Symptoms The treatment is commonly used to help manage symptoms related to inflammatory or irritative states, relevant for easing the discomfort associated with redness, swelling, and localized pain.

“It supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.”

Beyond dermatological use, it plays a role in managing ocular bacterial infections (e.g., conjunctivitis). Furthermore, in specific clinical settings, systemic forms may be part of symptomatic management for conditions presenting with systemic discomfort, such as infections affecting bone and joints. This application assists with maintaining a sense of stability when symptoms are more noticeable, supporting patients during episodes of heightened discomfort.

Official Eligibility Profile for Фуцидин (Fusidic Acid)

Official regulatory documents define specific populations who can and cannot use Фуцидин (Fusidic acid), focusing primarily on absolute contraindications and status-dependent restrictions. Eligibility is established for adults and the general pediatric population for both topical and systemic use, and older adults typically require no dosage adjustment.

---

Populations Who Must Not Use Фуцидин (Contraindications)

Category	Restriction
Hypersensitivity	Known allergy to fusidic acid or any excipients.
Systemic Co-administration	Patients concurrently taking Statins (HMG-CoA reductase inhibitors).
Hereditary Disorders	Patients with rare hereditary problems like fructose intolerance (for Oral Suspension).

---

Conditional or Restricted Eligibility

Use requires caution in patients with hepatic dysfunction or biliary tract obstruction when taking systemic forms, as the drug is primarily processed by the liver. For neonates, particular care is advised due to the theoretical risk related to bilirubin metabolism. Topical use is generally permitted during pregnancy and breastfeeding due to negligible systemic exposure, though application directly on the breast should be avoided. Systemic use during the third trimester of pregnancy should be avoided.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Фуцидин (Fusidic acid) as required by regulatory authorities, focusing exclusively on restrictions, prohibitions, and exposure changes.

Formal Restrictions and Contraindications

The co-administration of systemic Fusidic acid with HMG-CoA Reductase Inhibitors (Statins) is contraindicated in regulatory documents. This strict prohibition exists due to the documented risk of severe muscle damage, specifically rhabdomyolysis, when combining Fusidic acid with statins such as Simvastatin, Atorvastatin, and Rosuvastatin.

Pharmacokinetic and Pharmacodynamic Interactions

Fusidic acid is classified as a weak inhibitor of the CYP3A4 enzyme. This pharmacokinetic interaction can lead to increased plasma concentrations of co-administered medicines that are metabolized by this pathway. Specific examples noted in labeling include Ciclosporin and certain HIV Protease Inhibitors (e.g., Ritonavir).

Separately, a pharmacodynamic potentiation is documented with oral anticoagulants (Coumarin derivatives, e.g., Warfarin). Co-administration may result in an increased International Normalized Ratio (INR) and a heightened risk of bleeding, requiring regulatory caution.

Population-Specific Interaction Notes

Official labeling states that the interaction risk for CYP3A4 substrates may be heightened in patient populations with documented impaired liver function (hepatic impairment).

The Mechanism of Fusidic Acid

The action of Fusidic acid is defined by its selective interference with the bacterial cell's protein-building machinery, which is designed to halt microbial growth and division. The drug acts as a non-competitive inhibitor that targets the bacterial enzyme Elongation Factor G (EF-G) within the ribosomal complex, exploiting a structural difference that results in selective toxicity against prokaryotic systems. By binding to and stabilizing the EF-G-Ribosome-GDP complex, the drug physically halts the translocation phase, preventing the creation of new proteins necessary for the pathogen's survival and replication. The subsequent cessation of growth results in a bacteriostatic effect, which establishes a static microbial state. This mechanism is countered by bacterial resistance factors, such as the extitFusB protein, which actively releases the EF-G from the drug-bound complex, or by extitfusA gene mutations that reduce binding affinity, both of which restore the functional activity of EF-G.

The administration of Fusidic acid (Фуцидин) is structured by official guidelines, defining four approved administration methods: topical (cutaneous), ophthalmic, oral, and intravenous (IV) infusion. The specific route and dosage form selected depend on the location and type of infection being addressed.

---

Official Dosing Regimens and Frequency

Systemic use (oral tablets or IV infusion) for adults typically involves a dose of 500 mg, administered in divided doses three times daily (TID). In cases of severe infection, this systemic dose may be increased to 1 g TID. For pediatric patients, the systemic dose is calculated based on body weight, generally ranging from 20 to 50 mg/kg daily, administered in three doses.

Topical formulations (cream or ointment) are applied as a thin layer to the affected area. The frequency is typically two to four times daily for uncovered lesions, or reduced to once or twice daily if an occlusive dressing is used. Ophthalmic treatment requires instillation of one drop twice daily.

---

Duration and Administration Constraints

Official guidelines define specific time limits for treatment. Topical use is generally restricted to a maximum of 14 days to minimize the development of antimicrobial resistance. Ophthalmic courses often require the medicine to be continued for a minimum of 48 hours after symptoms have clinically cleared. Procedurally, the IV infusion must be administered slowly, requiring a minimum duration of 2 hours. Furthermore, contact lenses must be removed and not worn throughout the course of ophthalmic treatment.

Research Evidence Overview of Studies for Фуцидин

This section summarizes the high-level research landscape for Fusidic acid, focusing only on the types of clinical studies that underpin its use across various formulations, as reported by regulators and major scientific reviews. Research helps show what has been observed so far in study populations and contributes to the broader evidence landscape, but research does not determine whether an individual will respond similarly.

---

Evidence for Topical Use in Bacterial Skin Infections

Studies have been conducted using the topical cream and ointment forms of Фуцидин (Fusidic acid) for conditions that were studied such as impetigo and other localized bacterial skin and soft tissue infections. The research base is primarily structured around short-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies primarily monitored outcomes related to physical discomfort and outcomes reflecting acute changes in the infection, such as the change in visible signs like redness, crusting, and pustules. Researchers also examined Bacteriological Endpoints, which tracked changes in the bacteria measured in samples.

Studies reported measurements of changes in clinical signs in the observed populations over the 7-to-10-day treatment period. Research provides context about symptom patterns observed in these short-term infection scenarios. What remains uncertain is the full characterization of long-term outcomes beyond the immediate follow-up period documented in the trials. Existing research provides limited information on the long-term impact of widespread topical use on antimicrobial resistance development.

---

Evidence for Ophthalmic Use in Bacterial Eye Infections

Research has also been conducted on the ophthalmic eye drop formulation for conditions that were studied such as bacterial conjunctivitis. This area of research utilized Randomized Controlled Trials (RCTs), sometimes comparing the eye drops to other available ophthalmic antibiotics. Studies monitored Clinical Endpoints, which tracked changes in ocular symptoms like discharge and redness, and microbial outcomes (such as the presence of bacteria in samples).

Comparative trials reported patterns where measurements for clinical outcomes were described relative to the comparator treatment studied. The specialized viscous formulation was evaluated in studies examining patient-reported experiences related to the eye drops. What remains uncertain is the consistency and methodological rigor of some of the research; systematic reviews have indicated that evidence quality varies across studies due to design limitations in some older trials.

Key Studies & References

1. Clinical Use and Efficacy of Fusidic Acid in Ophthalmic Infections
2. Clinical Trial Study Details: Ophthalmic Fusidic Acid for Bacterial Conjunctivitis (NCT06911424)

Common questions about Фуцидин (FAQ)

Q: Is it common to feel a mild stinging or burning when first applying Фуцидин?

A: According to official product information, stinging, burning, or irritation at the application site are reported as side effects. For the cream and ointment, these are typically listed as uncommon, meaning they may affect up to 1 in 100 people. For the official eye drop formulation, however, these sensations are commonly reported.

Q: Can Фуцидин be used for fungal infections?

A: Official regulatory documents define Fusidic acid (Фуцидин) as an antibacterial agent. Its primary mechanism of action targets bacterial cells to stop their growth. Therefore, official indications state that the drug is used to treat bacterial skin infections and is not indicated for the treatment of fungal infections.

Q: How long after opening the tube is Фуцидин still effective?

A: Regulatory guidance provides specific time limits for maintaining product quality after the package is opened. Official safety documents generally recommend discarding the tube of topical medication after a set period from first use, which is commonly 28 days (4 weeks) but can vary up to 60 days based on the formulation and regional requirements. Information regarding the expiration after opening is detailed in the specific patient information leaflet.

Q: Is Фуцидин used for skin conditions other than bacterial infections?

A: The drug's use is strictly tied to its approved therapeutic indications. Official product information states that it is specifically indicated for conditions where the skin is infected by types of bacteria sensitive to Fusidic acid. The drug is not approved for use against viral, fungal, or non-infectious skin conditions.

Q: What ingredients in Фуцидин might cause an allergic reaction?

A: Official labels describe both the active and inactive ingredients of the formulation. Certain non-medicinal ingredients (excipients) in the product, such as cetyl alcohol, potassium sorbate, or butylhydroxyanisole, are noted in regulatory documents because they carry the potential to cause local skin reactions like contact dermatitis in individuals sensitive to those specific components.

Q: Can older adults use Фуцидин safely?

A: Official guidance indicates that topical cream, ointment, and eye drops are described in official guidance as being used by most adults, including older adults. For the topical forms, regulatory documents typically do not specify unique dose adjustments or special precautions needed specifically for the geriatric population.

Q: Is there any official information on using Фуцидин during the first trimester of pregnancy?

A: Regulatory safety information generally covers the use of topical Fusidic acid throughout pregnancy as a whole. While specific trimester-by-trimester data is often limited, Regulatory documents indicate that the use of the drug requires a professional assessment of the potential benefits versus the potential risks.

Q: What should I do if I accidentally get Фуцидин in my eye?

A: In cases of accidental eye contact with topical formulations, official safety documents describe the standard first aid procedure as rinsing the affected eye immediately with plenty of clean water for several minutes. If irritation or other symptoms persist, regulatory documents indicate that medical assistance should be sought.

Q: Does the efficacy of Фуцидин depend on the type of skin infection?

A: The effectiveness of the drug is primarily dependent upon its approved use, which is for infections caused by bacteria known to be sensitive to Fusidic acid. Official indications do not include use against infections caused by bacteria that are resistant to it or by other types of non-target pathogens.

Q: Is it normal for the treated area to appear dry after using the cream?

A: Dry skin at the application site is listed as a potential side effect in official product information. While generally considered an uncommon or rare event, depending on the formulation, it is a documented local effect of using the cream or ointment.

Q: Are there any known interactions between Фуцидин and common vitamins or supplements?

A: Official regulatory information on topical Fusidic acid typically notes that there are no known or documented problems when using the medication concurrently with common vitamins, herbal remedies, or supplements.

Q: What official bodies regulate the use and safety of Фуцидин?

A: The use and safety of this drug are regulated by various national and intergovernmental health authorities globally. These bodies include organizations such as the European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, Health Canada, and the Therapeutic Goods Administration (TGA) in Australia.

How to Store and Dispose of Фуцидин?

The storage of Фуцидин (Fusidic acid) must strictly adhere to regulatory requirements to maintain product stability and safety. Topical creams and eye drops must be stored below 25 C, while tablets and ointment must be kept below 30 C. All forms must be protected from freezing, moisture, and direct light, and kept in a closed container.

A critical requirement is the in-use stability period: opened tubes of cream and eye drops must typically be discarded after 4 weeks (28–30 days). A mandatory safety rule is to keep the medicine out of the sight and reach of children.

For disposal, unused or expired product must not be thrown away via household waste or flushed down wastewater. Instead, it must be disposed of in accordance with local regulatory requirements, often by returning it to a pharmacy. Additionally, topical forms carry a warning that exposed fabrics may pose a fire hazard.